title: A phase II study of paclitaxel and carboplatin with a biweekly schedule in patients with epithelial ovarian cancer: Gynecologic Cancer Network trial.
abstract: OBJECTIVE
  The objective of this multicenter phase II study was to evaluate the effects of biweekly paclitaxel and carboplatin combination chemotherapy on response rate and toxicities in patients with epithelial ovarian cancer.
  
  
  METHODS
  Patients with International Federation of Gynecology and Obstetrics stage II to IV ovarian cancer received paclitaxel at a dose of 120 mg/m(2) and carboplatin at an area under the curve of 3 mg/mL per minute every 2 weeks for 8 or more cycles. Inclusion criteria included an Eastern Cooperative Oncology Group performance status of 0 to 2 and no previous chemotherapy. Informed consent was obtained from each patient before the start of treatment.
  
  
  RESULTS
  From March 2003 through July 2009, 42 patients from 5 institutions were eligible to be evaluated for response and toxicity. The median age was 60.5 years (age range, 34-81 years). The International Federation of Gynecology and Obstetrics stage was stage II in 3 patients, stage III in 31 patients, and stage IV in 8 patients. The response rate was 66.7% (95% confidence interval: 50.5%-80.4%). Sixty-nine percent (29 of 42) of patients received 8 or more cycles of chemotherapy. The median progression-free survival was 18.5 months, and overall survival was 59.1 months. The most common grade 3 or 4 hematological toxicity was neutropenia (61.0%). No patients had grade 3 or 4 thrombocytopenia. The most common grade 3 nonhematological toxicities were neuropathy (4.9%) and nausea (2.4%).
  
  
  CONCLUSIONS
  Paclitaxel combined with carboplatin using a biweekly schedule is a safe and effective chemotherapy regimen for patients with epithelial ovarian cancer. Our results suggest that a biweekly schedule is well tolerated and is less toxic than a triweekly schedule.
authors.affiliation: Department of Obstetrics and Gynecology, Nippon Medical School Hospital.
authors.forename: Koichi
authors.initials: K
authors.lastname: Yoneyama
authors.forename: Hideki
authors.initials: H
authors.lastname: Konishi
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Yahata
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Fujita
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Aoki
authors.forename: Daisuke
authors.initials: D
authors.lastname: Doi
authors.forename: Takashi
authors.initials: T
authors.lastname: Matsushima
authors.forename: Shoji
authors.initials: S
authors.lastname: Kodama
authors.forename: Shigeru
authors.initials: S
authors.lastname: Honma
authors.forename: Hisamori
authors.initials: H
authors.lastname: Kato
authors.forename: Hiroki
authors.initials: H
authors.lastname: Nakayama
authors.forename: Seiryu
authors.initials: S
authors.lastname: Kamoi
authors.forename: Hirobumi
authors.initials: H
authors.lastname: Asakura
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Takeshita
authors.forename: Kenichi
authors.initials: K
authors.lastname: Tanaka
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D016190:Carboplatin / Q000008:administration & dosage; D000077216:Carcinoma, Ovarian Epithelial; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008875:Middle Aged; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D016190:Carboplatin; D017239:Paclitaxel